STRAP、Ki-67表达对乳腺癌新辅助化疗后肿瘤残余的评估价值  

Evaluation value of STRAP and Ki-67 Expression in Breast Cancer after Neoadjuvant Chemotherapy

作　　者：张伟强 王凤琴 姚文娟 吴冬梅 仝志超 张婉琳 于婧 ZHANG Wei-qiang;WANG Feng-qin;YAO Wen-juan;WU Dong-mei;TONG Zhi-chao;ZHANG Wan-lin;YU Jing(Department of Pathology,Hebei Petro China Central Hospital,Lang fang 065000,China)

机构地区：[1]河北中石油中心医院病理科,廊坊065000

出　　处：《微循环学杂志》2022年第4期47-52,共6页Chinese Journal of Microcirculation

基　　金：廊坊市科学技术研究与发展计划项目(2020013088)。

摘　　要：目的:探讨丝氨酸-苏氨酸激酶受体相关蛋白(STRAP)、增殖指数Ki-67表达在乳腺癌新辅助化疗后肿瘤组织残余评估中的价值。方法:选取2020-01-2021-05在本院就诊的乳腺癌患者100例(乳腺癌组),给予新辅助化疗。根据Miller-Payne病理评价系统,将100例患者分为病理完全缓解组(qCR组,n=21)和非病理完全缓解组(非qCR组,n=79)。同时选取乳腺癌良性病变患者50例(乳腺良性病变组),采用免疫组化法检测化疗前病灶STRAP、Ki-67表达。结果:乳腺癌组织Ki-67和STRAP阳性表达率分别为(35.54±9.97)%和78.00%,明显高于乳腺良性病变组织[(7.22±1.13)%和36.00%,P<0.01)]。TNM分期Ⅲ期、中低分化乳腺癌组织Ki-67为(40.52±6.14)%和(36.98±8.12)%,分别明显高于ⅡB期和高分化组织[(32.22±5.94)%和(33.71±7.03)%,P<0.05或P<0.01)];肿瘤直径≥5cm、TNM分期Ⅲ期乳腺癌组织STRAP阳性表达率分别为91.53%和95.00%,分别明显高于肿瘤直径<5cm、ⅡB期组织(58.54%和66.67%,P<0.01)。qCR组患者Ki-67和STRAP阳性表达率分别为(28.87±4.45)%和52.38%,明显低于非qCR组患者[(37.31±7.20)%和84.81%,P<0.01)]。Ki-67联合STRAP预测非qCR的ROC曲线下面积为0.819,明显高于Ki-67、STRAP单独预测的0.711和0.632(P<0.01),灵敏度和特异度分别为84.50%和87.00%。结论:乳腺癌患者STRAP、Ki-67表达明显增强,与其TNM分期、肿瘤直径、分化程度有一定关系;STRAP联合Ki-67对预测新辅助化疗后肿瘤残余有一定应用价值。Objective:To investigate the value of serine threonine kinase receptor associated protein(STRAP)and proliferation index Ki-67 expression in residual tumor tissue after neoadjuvant chemotherapy for breast cancer.Method:From 2020-01 to 2021-05,100 breast cancer patients in our hospital were selected,and 50 patients with benign breast cancer were selected,the expression of STRAP and Ki-67 before chemotherapy was detected by immunohistochemistry,the breast cancer patients were treated with neoadjuvant chemotherapy.Results:The positive expression rates of Ki-67 and STRAP in breast cancer tissues were(35.54±9.97)%and 78%,respectively,which were significantly higher than those in benign breast lesions[(7.22±1.13)%and 36.00%,P<0.01)].The Ki-67 of TNM stage III and moderately poorly differentiated breast cancer was(40.52±6.14)%and(36.98±8.12)%respectively,which was significantly higher than that of stage IIB and high differentiated tissues[(32.22±5.94)%and(33.71±7.03)%,P<0.05 or P<0.01)].The positive expression rate of STRAP in stage III breast cancer with diameter of≥5cm or TNM was 91.53%and 95%respectively,which was significantly higher than that of tumor diameter<5cm and II B stage(58.54%and 66.67%,P<0.01).After neoadjuvant chemotherapy,21 patients achieved pathological complete remission(qCR)and 79 patients without pathological complete remission(non qCR).The positive expression rates of Ki-67 and strap in qCR patients were(28.87±4.45)%and 52.38%,respectively,which were significantly lower than those in non qCR patients[(37.31±7.20)%and 84.81%,P<0.01)].The area under the ROC curve predicted by Ki-67 combined with STRAP was 0.819,which was significantly higher than that predicted by Ki-67 and STRAP alone(0.711 and 0.632,P<0.01).The sensitivity and specificity were 84.50%and 87.00%,respectively.Conclusion:The expression of STRAP and Ki-67 in breast cancer patients is significantly increased,which is related to TNM stage,tumor diameter and differentiation degree.STRAP combined with Ki-67 has certain application

关 键 词：丝氨酸-苏氨酸激酶受体相关蛋白 增殖指数 KI-67 乳腺癌 新辅助化疗 

分 类 号：K737.9[历史地理—历史学]